Filing Flows › Protalix BioTherapeutics (PLX) › Net income
Protalix BioTherapeutics (PLX) net income by quarter
Protalix BioTherapeutics' net income was $3.8M in Q2 2026 (second quarter 2026), -79% from Q1 2026. Over the last 5 quarters it ranged from $164K (Q2 2025) to $18.3M (Q1 2026).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $3.8M | -79% | 23× |
| Q1 2026 | $18.3M | +678% | — |
| Q3 2025 | $2.4M | 14× | — |
| Q2 2025 | $164K | -97% | — |
| Q4 2024 | $6.5M | — | — |
Q2 2026 at a glance
Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Protalix BioTherapeutics' net income?
Protalix BioTherapeutics' net income was $3.8M in Q2 2026 (second quarter 2026), -79% from Q1 2026.
How has Protalix BioTherapeutics' net income changed?
Over the last 5 quarters it ranged from $164K (Q2 2025) to $18.3M (Q1 2026).
Q2 2026 results → · How Protalix BioTherapeutics makes money →